FDA Cmte. Will Discuss Standards For Abuse-Deterrant Pain Drugs, With Focus On Embeda

Approvability of Alpharma’s abuse-resistant morphine Embeda will facilitate a broader discussion of approval standards by advisory committees Nov. 14.